Sermin Borekci

Sermin Borekci

Auto-generated profile, based on publicly available information

Sermin Borekci

Department of Pulmonology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MGMustafa Sait Gönen
Mustafa Sait Gönen
MAMerve Alaylıoğlu
Merve Alaylıoğlu
EDEmre Durcan
Emre Durcan
YÖYusuf Özdemir
Yusuf Özdemir
SŞSerdar Şahin
Serdar Şahin
EDErdinç Dursun
Erdinç Dursun
Background: We aimed to establish an acute treatment protocol to increase serum vitamin D, evaluate the effectiveness of vitamin D3 supplementation, and reveal the potential mechanisms in COVID-19. Methods: We retrospectively analyzed the data of 867 COVID-19 cases. Then, a prospective study was conducted, including 23 healthy individuals and 210 cases. A total of 163 cases had vitamin D supplementation, and 95 were followed for 14 days. Clinical outcomes, routine blood biomarkers, serum levels of vitamin D metabolism, and action mechanism-related parameters were evaluated. Results: Our treatment protocol increased the serum 25OHD levels significantly to above 30 ng/mL within two weeks. COVID-19 cases (no comorbidities, no vitamin D treatment, 25OHD <30 ng/mL) had 1.9-fold increased risk of having hospitalization longer than 8 days compared with the cases with comorbidities and vitamin D treatment. Having vitamin D treatment decreased the mortality rate by 2.14 times. The correlation analysis of specific serum biomarkers with 25OHD indicated that the vitamin D action in COVID-19 might involve regulation of INOS1, IL1B, IFNg, cathelicidin-LL37, and ICAM1. Conclusions: Vitamin D treatment shortened hospital stay and decreased mortality in COVID-19 cases, even in the existence of comorbidities. Vitamin D supplementation is effective on various target parameters; therefore, it is essential for COVID-19 treatment.

1 July 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
NKNurdan Kokturk
Nurdan Kokturk
CBCenk Babayigit
Cenk Babayigit
SKSeval Kul
Seval Kul
PÇPelin Duru Çetinkaya
Pelin Duru Çetinkaya
SNSibel Atis Nayci
Sibel Atis Nayci
HBHasan Bayram
Hasan Bayram

21 January 2019 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
GUGaye Ulubay
Gaye Ulubay
ADAsli Gorek Dilektasli
Asli Gorek Dilektasli
SBSermin Borekci
Sermin Borekci
OYOznur YILDIZ
Oznur YILDIZ
EKEsen Kiyan
Esen Kiyan
SSSevgi Saryal
Sevgi Saryal
Turkthoracj, Turkish Thoracic Journal

30 April 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
RSRabia Bag Soytas
Rabia Bag Soytas
MEMurat Esmer
Murat Esmer
PAPınar Arman
Pınar Arman
VSVeysel Suzan
Veysel Suzan
TGTuğçe EMİROĞLU GEDİK
Tuğçe EMİROĞLU GEDİK
ADAlper Doventas
Alper Doventas
Background/aim: We aimed to investigate the factors affecting the mortality of patients aged 65 years or older who were hospitalized with the diagnosis of new coronavirus pneumonia (COVID-19). Materials and methods: This is a retrospective study of patients 65 years old or older with COVID-19 who were hospitalized in Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Hospital, between March 11 and May 28, 2020. Demographic, clinical, treatment, and laboratory data were extracted from electronic medical records. We used univariate and multivariate logistic regression methods to explore the risk factors for in-hospital death. Results: A total of 218 patients (112 men, 106 women) were included, of whom 166 were discharged and 52 died in hospital. With univariate analysis, various clinical features and laboratory variables were found to be significantly different (i.e. P < 0.05). In multivariate logistic regression analysis the following were independently associated with mortality: present malignancy [odds ratio (OR) = 4.817, 95% confidence interval (CI) = 1.107-20.958, P: 0.036]; dyspnea (OR = 4.652, 95% CI = 1.473-14.688, P: 0.009); neutrophil/lymphocyte ratio (NLR; OR = 1.097, 95% CI = 1.012-1.188, P: 0.025); the highest values of C-reactive protein (CRP; OR = 1.006, 95% CI = 1.000-1.012, P: 0.049), lactate dehydrogenase (LDH; OR = 1.002, 95% CI = 1.001-1.004, P: 0.003), and creatinine levels (OR = 1.497, 95% CI = 1.126-1.990, P: 0.006); oxygen saturation (SpO2) values on admission (OR = 0.897, 95% CI = 0.811-0.993, P: 0.036); and azithromycin use (OR = 0.239, 95% CI = 0.065-0.874, P: 0.031). Conclusion: The presence of malignancy; symptoms of dyspnea; high NLR; highest CRP, LDH, and creatinine levels; and low SpO2 on admission predicted mortality. On the other hand, azithromycin use was found to be protective against mortality. Knowing the causes predicting mortality will be important to treat future cases more successfully.

12 May 2020 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
SGSule Gundogdu
Sule Gundogdu
SBSermin Borekci
Sermin Borekci
EAErsan Atahan
Ersan Atahan
BMBenan Musellim
Benan Musellim

2 June 2020 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
BGBilun Gemicioglu
Bilun Gemicioglu
SBSermin Borekci
Sermin Borekci
ADAsli Gorek Dilektasli
Asli Gorek Dilektasli
GUGaye Ulubay
Gaye Ulubay
OAOzlem Azap
Ozlem Azap
SSSevgi Saryal
Sevgi Saryal
Coronavirus,pulmonary function tests,triage,pandemic